Annals of Hematology

, Volume 85, Issue 7, pp 424–433

Management of sepsis in neutropenia: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

  • Olaf Penack
  • Thomas Beinert
  • Dieter Buchheidt
  • Hermann Einsele
  • Holger Hebart
  • Michael G. Kiehl
  • Gero Massenkeil
  • Xaver Schiel
  • Jan Schleicher
  • Philipp B. Staber
  • Stefan Wilhelm
  • Hans Wolf
  • Helmut Ostermann
Original Article

Abstract

These guidelines from the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO) give recommendations for the management of adults with neutropenia and the diagnosis of sepsis. The guidelines are written for clinicians and focus on pathophysiology, diagnosis, and treatment of sepsis. The manuscript contains evidence-based recommendations for the assessment of the quality and strength of the data.

Keywords

Guideline Sepsis Neutropenia Treatment 

References

  1. 1.
    EORTC International Antimicrobial Therapy Project Group (1984) Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. J Infect Dis 150:372–379Google Scholar
  2. 2.
    Cochrane Injuries Group Albumin Reviewers (1998) Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ 317:235–240Google Scholar
  3. 3.
    Alejandria MM, Lansang MA, Dans LF, Mantaring JB (2005) Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev Oxford (update software)Google Scholar
  4. 4.
    Alouf JE, H Muller-Alouf (2003) Staphylococcal and streptococcal superantigens: molecular, biological and clinical aspects. 292:429–440Google Scholar
  5. 5.
    Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871PubMedGoogle Scholar
  6. 6.
    Astiz ME, Rackow EC (1999) Crystalloid–colloid controversy revisited. Crit Care Med 27:34–35PubMedGoogle Scholar
  7. 7.
    Azoulay E, Darmon M, Delclaux C, Fieux F, Bornstain C, Moreau D, Attalah H, Le Gall JR, Schlemmer B (2002) Deterioration of previous acute lung injury during neutropenia recovery. Crit Care Med 30:781–786PubMedGoogle Scholar
  8. 8.
    Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J (2000) Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356:2139–2143PubMedGoogle Scholar
  9. 9.
    Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204–R212PubMedGoogle Scholar
  10. 10.
    Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA, Colardyn FA (2003) Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit Care Med 31:104–112PubMedGoogle Scholar
  11. 11.
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedGoogle Scholar
  12. 12.
    Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340PubMedGoogle Scholar
  13. 13.
    Boldt J, Muller M, Mentges D, Papsdorf M, Hempelmann G (1998) Volume therapy in the critically ill: is there a difference? Intensive Care Med 24:28–36PubMedGoogle Scholar
  14. 14.
    Bourgoin A, Leone M, Delmas A, Garnier F, Albanese J, Martin C (2005) Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Crit Care Med 33:780–786PubMedGoogle Scholar
  15. 15.
    Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27:723–732PubMedGoogle Scholar
  16. 16.
    Buchman AL (2001) Glutamine: commercially essential or conditionally essential? A critical appraisal of the human data. Am J Clin Nutr 74:25–32PubMedGoogle Scholar
  17. 17.
    Choi PT, Yip G, Quinonez LG, Cook DJ (1999) Crystalloids vs colloids in fluid resuscitation: a systematic review. Crit Care Med 27:200–210PubMedGoogle Scholar
  18. 18.
    Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198–4214PubMedGoogle Scholar
  19. 19.
    Cohen J (2002) The immunopathogenesis of sepsis. Nature 420:885–891PubMedGoogle Scholar
  20. 20.
    Conti G, Marino P, Cogliati A, Dell’Utri D, Lappa A, Rosa G, Gasparetto A (1998) Noninvasive ventilation for the treatment of acute respiratory failure in patients with hematologic malignancies: a pilot study. Intensive Care Med 24:1283–1288PubMedGoogle Scholar
  21. 21.
    Cooper MS, Stewart PM (2003) Corticosteroid insufficiency in acutely ill patients. N Engl J Med 348:727–734PubMedGoogle Scholar
  22. 22.
    Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ Jr (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23:1430–1439PubMedGoogle Scholar
  23. 23.
    Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E (1996) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795–805PubMedGoogle Scholar
  24. 24.
    Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE (1991) Endotoxemia in human septic shock. Chest 99:169–175PubMedGoogle Scholar
  25. 25.
    Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglund A (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37:333–340PubMedGoogle Scholar
  26. 26.
    Desjars P, Pinaud M, Bugnon D, Tasseau F (1989) Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 17:426–429PubMedGoogle Scholar
  27. 27.
    Elting LS, Rubenstein EB, Rolston KV, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25:247–259PubMedGoogle Scholar
  28. 28.
    Emerson TE Jr, Fournel MA, Leach WJ, Redens TB (1987) Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat. Circ Shock 21:1–13PubMedGoogle Scholar
  29. 29.
    Emerson TE Jr, Fournel MA, Redens TB, Taylor FB Jr (1989) Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 87:27S–33SPubMedGoogle Scholar
  30. 30.
    Engel A, Kern P, Kern WV (1996) Levels of cytokines and cytokine inhibitors in the neutropenic patient with alpha-hemolytic streptococcus shock syndrome. Clin Infect Dis 23:785–789PubMedGoogle Scholar
  31. 31.
    Feinstein DI (1982) Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 60:284–287PubMedGoogle Scholar
  32. 32.
    Finney SJ, Zekveld C, Elia A, Evans TW (2003) Glucose control and mortality in critically ill patients. JAMA 290:2041–2047PubMedGoogle Scholar
  33. 33.
    Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E (1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334:1697–1702PubMedGoogle Scholar
  34. 34.
    Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271:1836–1843PubMedGoogle Scholar
  35. 35.
    Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22:12–21PubMedGoogle Scholar
  36. 36.
    Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101:816–823PubMedGoogle Scholar
  37. 37.
    Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882–888PubMedGoogle Scholar
  38. 38.
    Freeman BD, Buchman TG (2000) Gene in a haystack: tumor necrosis factor polymorphisms and outcome in sepsis. Crit Care Med 28:3090–3091PubMedGoogle Scholar
  39. 39.
    Fukuoka T, Nishimura M, Imanaka H, Taenaka N, Yoshiya I, Takezawa J (1989) Effects of norepinephrine on renal function in septic patients with normal and elevated serum lactate levels. Crit Care Med 17:1104–1107PubMedGoogle Scholar
  40. 40.
    Girbes AR, Patten MT, McCloskey BV, Groeneveld AB, Hoogenberg K (2000) The renal and neurohumoral effects of the addition of low-dose dopamine in septic critically ill patients. Intensive Care Med 26:1685–1689PubMedGoogle Scholar
  41. 41.
    Goodman S, Sprung CL, Ziegler D, Weiss YG (2005) Cortisol changes among patients with septic shock and the relationship to ICU and hospital stay. Intensive Care MedGoogle Scholar
  42. 42.
    Grimminger F, Mayer K, Seeger W (1997) Is there a reliable immunotherapy in infection? Internist (Berl) 38:541–552Google Scholar
  43. 43.
    Hartmann P, Lammertink J, Mansmann G, Hubel K, Salzberger B, Stutzer H, Engert A, Fatkenheuer G (2005) A randomized, placebo-controlled study of the use of filgrastim in non-neutropenic patients with nosocomial pneumonia. Eur J Med Res 10:29–35PubMedGoogle Scholar
  44. 44.
    Hauptman JG, Hassouna HI, Bell TG, Penner JA, Emerson TE (1988) Efficacy of antithrombin III in endotoxin-induced disseminated intravascular coagulation. Circ Shock 25:111–122PubMedGoogle Scholar
  45. 45.
    Hesselvik JF, Blomback M, Brodin B, Maller R (1989) Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 17:724–733PubMedGoogle Scholar
  46. 46.
    Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U (2001) Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 286:944–953PubMedGoogle Scholar
  47. 47.
    Hilbert G, Gruson D, Vargas F, Valentino R, Chene G, Boiron JM, Pigneux A, Reiffers J, Gbikpi-Benissan G, Cardinaud JP (2000) Noninvasive continuous positive airway pressure in neutropenic patients with acute respiratory failure requiring intensive care unit admission. Crit Care Med 28:3185–3190PubMedGoogle Scholar
  48. 48.
    Hilbert G, Gruson D, Vargas F, Valentino R, Gbikpi-Benissan G, Dupon M, Reiffers J, Cardinaud JP (2001) Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med 344:481–487PubMedGoogle Scholar
  49. 49.
    Horn DL, Morrison DC, Opal SM, Silverstein R, Visvanathan K, Zabriskie JB (2000) What are the microbial components implicated in the pathogenesis of sepsis? Report on a symposium. Clin Infect Dis 31:851–858PubMedGoogle Scholar
  50. 50.
    Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348:138–150PubMedGoogle Scholar
  51. 51.
    Kaminski MV Jr, Blumeyer TJ (1993) Metabolic and nutritional support of the intensive care patient. Ascending the learning curve. Crit Care Clin 9:363–376PubMedGoogle Scholar
  52. 52.
    Karlin L, Darmon M, Thiery G, Ciroldi M, de Miranda S, Lefebvre A, Schlemmer B, Azoulay E (2005) Respiratory status deterioration during G-CSF-induced neutropenia recovery. Bone Marrow Transplant 36:245–250PubMedGoogle Scholar
  53. 53.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104PubMedGoogle Scholar
  54. 54.
    Kellum JA, Angus DC, Johnson JP, Leblanc M, Griffin M, Ramakrishnan N, Linde-Zwirble WT (2002) Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med 28:29–37PubMedGoogle Scholar
  55. 55.
    Kish MA (2001) Guide to development of practice guidelines. Clin Infect Dis 32:851–854PubMedGoogle Scholar
  56. 56.
    Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250–1256PubMedGoogle Scholar
  57. 57.
    Link H, Maschmeyer G, Meyer P, Hiddemann W, Stille W, Helmerking M, Adam D (1994) Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy. Ann Hematol 69:231–243PubMedGoogle Scholar
  58. 58.
    Lorente JA, Landin L, De Pablo R, Renes E, Liste D (1993) l-arginine pathway in the sepsis syndrome. Crit Care Med 21:1287–1295PubMedCrossRefGoogle Scholar
  59. 59.
    Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA (2000) A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 68:6398–6401PubMedGoogle Scholar
  60. 60.
    Lorenz E, Mira JP, Frees KL, Schwartz DA (2002) Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 162:1028–1032PubMedGoogle Scholar
  61. 61.
    Malay MB, Ashton RC Jr, Landry DW, Townsend RN (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47:699–703PubMedGoogle Scholar
  62. 62.
    Martin C, Papazian L, Perrin G, Saux P, Gouin F (1993) Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 103:1826–1831PubMedGoogle Scholar
  63. 63.
    Martin C, Viviand X, Leone M, Thirion X (2000) Effect of norepinephrine on the outcome of septic shock. Crit Care Med 28:2758–2765PubMedGoogle Scholar
  64. 64.
    Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554PubMedGoogle Scholar
  65. 65.
    McIntyre L, Hebert PC, Wells G, Fergusson D, Marshall J, Yetisir E, Blajchman MJ (2004) Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients? J Trauma 57:563–568PubMedGoogle Scholar
  66. 66.
    Meier-Hellmann A (2003) Standards in the diagnosis and treatment of sepsis. Anasthesio Intensivmed Notf Med Schmertzther 38:107–133Google Scholar
  67. 67.
    Mesters RM, Florke N, Ostermann H, Kienast J (1996) Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 75:902–907PubMedGoogle Scholar
  68. 68.
    Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J (1996) Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 88:881–886PubMedGoogle Scholar
  69. 69.
    Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, Whittaker BG, Taylor FB, Hack CE, Friedman B (2000) Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 95:1117–1123PubMedGoogle Scholar
  70. 70.
    Napolitano LM (2004) Current status of blood component therapy in surgical critical care. Curr Opin Crit Care 10:311–317PubMedGoogle Scholar
  71. 71.
    Oberholzer A, Oberholzer C, Moldawer LL (2001) Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16:83–96PubMedGoogle Scholar
  72. 72.
    Obritsch MD, Jung R, Fish DN, MacLaren R (2004) Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother 38:1117–1122PubMedGoogle Scholar
  73. 73.
    Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25:1115–1124PubMedGoogle Scholar
  74. 74.
    Ostermann H, Kratz-Albers K, Mesters RM, Kiehl M, Kienast J (1997) Reciprocal changes in circulating interleukin-6 and its soluble receptor during evolving sepsis in leukocytopenic patients. J Infect Dis 176:825–828PubMedGoogle Scholar
  75. 75.
    Ostermann H, Rothenburger M, Mesters RM, van de LJ, Kienast J (1994) Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br J Haematol 88:332–337PubMedGoogle Scholar
  76. 76.
    Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96:576–582PubMedGoogle Scholar
  77. 77.
    Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F, Kruithof EK (1989) Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 61:459–462PubMedGoogle Scholar
  78. 78.
    Regazzoni CJ, Khoury M, Irrazabal C, Myburg C, Galvalisi NR, O’Flaherty M, Sarquis SG, Poderoso JJ (2003) Neutropenia and the development of the systemic inflammatory response syndrome. Intensive Care Med 29:135–138PubMedGoogle Scholar
  79. 79.
    Riedemann NC, Guo RF, Ward PA (2003) The enigma of sepsis. J Clin Invest 112:460–467PubMedGoogle Scholar
  80. 80.
    Rinaldo JE, Borovetz H (1985) Deterioration of oxygenation and abnormal lung microvascular permeability during resolution of leukopenia in patients with diffuse lung injury. Am Rev Respir Dis 131:579–583PubMedGoogle Scholar
  81. 81.
    Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377PubMedGoogle Scholar
  82. 82.
    Roberts I, Alderson P, Bunn F, Chinnock P, Ker K, Schierhout G (2004) Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev CD000567Google Scholar
  83. 83.
    Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S, Vincent JL, Torres A, Rello J, Nelson S (2003) Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 31:367–373PubMedGoogle Scholar
  84. 84.
    Salvo I, de Cian W, Musicco M, Langer M, Piadena R, Wolfler A, Montani C, Magni E (1995) The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 21(Suppl 2):S244–S249PubMedGoogle Scholar
  85. 85.
    Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, Troner MB, Wagnon AH (2001) Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519–1538PubMedGoogle Scholar
  86. 86.
    Schonbohn H, Schuler M, Kolbe K, Peschel C, Huber C, Bemb W, Aulitzky WE (1995) Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia. Ann Hematol 71:161–168PubMedGoogle Scholar
  87. 87.
    Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L (2001) Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 357:911–916PubMedGoogle Scholar
  88. 88.
    Schrier RW, Wang W (2004) Acute renal failure and sepsis. N Engl J Med 351:159–169PubMedGoogle Scholar
  89. 89.
    Sculier JP, Paesmans M, Markiewicz E, Berghmans T (2000) Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit. Crit Care Med 28:2786–2792PubMedGoogle Scholar
  90. 90.
    Sevransky JE, Levy MM, Marini JJ (2004) Mechanical ventilation in sepsis-induced acute lung injury/acute respiratory distress syndrome: an evidence-based review. Crit Care Med 32:S548–S553PubMedGoogle Scholar
  91. 91.
    SharmaVK, Dellinger RP (2003) The International Sepsis Forum’s controversies in sepsis: my initial vasopressor agent in septic shock is norepinephrine rather than dopamine. Crit Care 7:3–5PubMedGoogle Scholar
  92. 92.
    Souba WW (1997) Nutritional support. N Engl J Med 336:41–48PubMedGoogle Scholar
  93. 93.
    Spahn DR, Marcucci C (2004) Blood management in intensive care medicine: CRIT and ABC—what can we learn? Crit Care 8:89–90PubMedGoogle Scholar
  94. 94.
    Stuber F (2001) Effects of genomic polymorphisms on the course of sepsis: is there a concept for gene therapy? J Am Soc Nephrol 12(Suppl 17):S60–S64PubMedGoogle Scholar
  95. 95.
    Tanaka H, Nishino M, Nakamori Y, Ogura H, Ishikawa K, Shimazu T, Sugimoto H (2001) Granulocyte colony-stimulating factor (G-CSF) stiffens leukocytes but attenuates inflammatory response without lung injury in septic patients. J Trauma 51:1110–1116PubMedCrossRefGoogle Scholar
  96. 96.
    Taylor RW, Manganaro L, O’Brien J, Trottier SJ, Parkar N, Veremakis C (2002) Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med 30:2249–2254PubMedGoogle Scholar
  97. 97.
    Thijs A, Thijs LG (1998) Pathogenesis of renal failure in sepsis. Kidney Int Suppl 66:S34–S37Google Scholar
  98. 98.
    Triantaphyllopoulos DC (1984) Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Thromb Haemost 51:232–235PubMedGoogle Scholar
  99. 99.
    Van den BG, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367Google Scholar
  100. 100.
    Van der Pol WL, Huizinga TW, Vidarsson G, van der Linden MW, Jansen MD, Keijsers V, de Straat FG, Westerdaal NA, de Winkel JG, Westendorp RG (2001) Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 184:1548–1555PubMedGoogle Scholar
  101. 101.
    Vincent JL (2001) Hemodynamic support in septic shock. Intensive Care Med 27(Suppl 1):S80–S92PubMedGoogle Scholar
  102. 102.
    Vincent JL, Abraham E, Annane D, Bernard G, Rivers E, Van den BG (2002) Reducing mortality in sepsis: new directions. Crit Care 6(Suppl 3):S1–S18PubMedGoogle Scholar
  103. 103.
    Vincent JL, Van der LP, Domb M, Blecic S, Azimi G, Bernard A (1987) Dopamine compared with dobutamine in experimental septic shock: relevance to fluid administration. Anesth Analg 66:565–571PubMedGoogle Scholar
  104. 104.
    Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869–1878PubMedGoogle Scholar
  105. 105.
    Weigand MA, Bardenheuer HJ, Bottiger BW (2003) Clinical management of patients with sepsis. Anaesthesist 52:3–22PubMedGoogle Scholar
  106. 106.
    Wilkes MM, Navickis RJ (2001) Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med 135:149–164PubMedGoogle Scholar
  107. 107.
    Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103–1110PubMedGoogle Scholar
  108. 108.
    Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, Collins RH, Stevens DA, Herzig GP (1993) High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med 118:937–942PubMedGoogle Scholar
  109. 109.
    Wunderink R, Leeper K Jr, Schein R, Nelson S, DeBoisblanc B, Fotheringham N, Logan E (2001) Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 119:523–529PubMedGoogle Scholar
  110. 110.
    Zimmerman JL (2004) Use of blood products in sepsis: an evidence-based review1. Crit Care Med 32:S542–S547PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Olaf Penack
    • 1
  • Thomas Beinert
    • 2
  • Dieter Buchheidt
    • 3
  • Hermann Einsele
    • 4
  • Holger Hebart
    • 5
  • Michael G. Kiehl
    • 6
  • Gero Massenkeil
    • 7
  • Xaver Schiel
    • 8
  • Jan Schleicher
    • 9
  • Philipp B. Staber
    • 10
  • Stefan Wilhelm
    • 11
  • Hans Wolf
    • 12
  • Helmut Ostermann
    • 8
  1. 1.Klinik für Hämatologie, Onkologie and TransfusionsmedizinCharité Campus Benjamin FranklinBerlinGermany
  2. 2.Abteilung für Innere Medizin mit Schwerpunkt Hämatologie und internistische OnkologieKlinik WartenbergWartenbergGermany
  3. 3.Medizinische Klinik, Universitätsklinikum MannheimRuprecht-Karls-Universität HeidelbergHeidelbergGermany
  4. 4.Medizinische Klinik und Poliklinik IIUniversitätsklinikum WürzburgWärzburgGermany
  5. 5.Zentrum für Innere MedizinKlinikum Schwäbisch GmündMutlangenGermany
  6. 6.Klinik für Innere MedizinKlinikum FrankfurtFrankfurtGermany
  7. 7.Medizinische Klinik mit Schwerpunkt Hämatologie und OnkologieCharité Campus Virchow-KlinikumBerlinGermany
  8. 8.Medizinische Klinik, Klinikum GrosshadernLudwig-Maximilians UniversitätMünchenGermany
  9. 9.Klinik für Hämatologie und OnkologieKatharinenhospital StuttgartStuttgartGermany
  10. 10.Abteilung für Hämatologie, Klinik für Innere MedizinMedizinische Universität GrazÖsterreichGermany
  11. 11.Abteilung für Hämatologie und Onkologie, Klinik für Innere MedizinUniversität RostockRostockGermany
  12. 12.Innere Medizin IV, Hämatologie/OnkologieMartin-Luther-Universität HalleHalleGermany

Personalised recommendations